Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease

被引：0
|
作者：
Ruotolo, Giacomo
Lincoff, Michael A.
Menon, Venu
McErlean, Ellen
Wolski, Kathy
Haas, Joseph V.
Weerakkody, Govinda
Riesmeyer, Jeffrey S.
Nissen, Steven E.
Nicholls, Stephen J.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Lipoproteins; Apolipoproteins; Cardiovascular disease; Atherosclerosis; CETP inhibitors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17400
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LDL-C Monitoring Frequency After the Diagnosis of Diabetes or Atherosclerotic Cardiovascular Disease
    Cohen, Sarah S.
    Chamberlain, Alanna M.
    Killian, Jill M.
    Monda, Keri L.
    Weston, Susan A.
    Okerson, Ted
    [J]. CIRCULATION, 2017, 136
  • [32] Should patients with high cardiovascular risk and an LDL-C concentration below 70 mg/dl be treated with aggressive statin therapy?
    Lee, Cheol Whan
    Park, Seung-Jung
    [J]. CLINICAL LIPIDOLOGY, 2012, 7 (01) : 1 - 4
  • [33] Cardiovascular Event Rates According to Low-density Lipoprotein Cholesterol Level Among Statin-treated Patients With Existing Cardiovascular Disease
    Chamberlain, Alanna M.
    Cohen, Sarah S.
    Weston, Susan A.
    Fox, Kathleen M.
    Xiang, Pin
    Killian, Jill M.
    Qian, Yi
    [J]. CIRCULATION, 2017, 136
  • [34] Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
    Wong, Nathan D.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
  • [35] Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
    Packard, Chris J.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (03) : 133 - 142
  • [36] Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia
    Kastelein, John J. P.
    HaIlen, Jonas
    Vige, Runar
    Fraser, David A.
    Zhou, Rong
    Hustvedt, Svein Olaf
    Orloff, David G.
    Bays, Harold E.
    [J]. CARDIOLOGY, 2016, 135 (01) : 3 - 12
  • [37] Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
    Chris J. Packard
    [J]. Current Atherosclerosis Reports, 2022, 24 : 133 - 142
  • [38] Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease
    Klug, E. Q.
    Raal, E. J.
    [J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2024, 114 (05): : 8 - 8
  • [39] Echolucency of Carotid Plaque Is Useful for Assessment of Residual Cardiovascular Risk in Patients With Chronic Coronary Artery Disease Who Achieve LDL-C Goals on Statin Therapy
    Uematsu, Manabu
    Nakamura, Takamitsu
    Sugamata, Wataru
    Kitta, Yoshinobu
    Fujioka, Daisuke
    Saito, Yukio
    Kawabata, Ken-ichi
    Obata, Jun-ei
    Watanabe, Yosuke
    Watanabe, Kazuhiro
    Kugiyama, Kiyotaka
    [J]. CIRCULATION JOURNAL, 2014, 78 (01) : 151 - 158
  • [40] Plaque Echoluceney of Carotid Artery is Useful for Assessment of Residual Cardiovascular Risk in Patients with Coronary Artery Disease after Achievement of LDL-C Goals on Statin Therapy
    Uematsu, Manabu
    Nakamura, Takamitsu
    Futamata, Mika
    Mochida, Tetsuji
    Nakamura, Jun
    Sugamata, Wataru
    Deyama, Juntarou
    Fujioka, Daisuke
    Saitou, Yukio
    Kitta, Yoshinobu
    Kawabata, Ken-ichi
    Obata, Jun-ei
    Kugiyama, Kiyotaka
    [J]. CIRCULATION, 2012, 126 (21)
12345